David N Krag
Overview
Explore the profile of David N Krag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1961
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fanning J, Kalsi S, Krag D
Int J Dermatol
. 2023 Apr;
62(7):850-856.
PMID: 37073701
The ongoing challenges posed by COVID-19 are concerning for their impact on successful detection and recognition of melanoma as total body skin examinations and skin biopsies are critical for identifying...
2.
Shukla G, Pero S, Mei L, Sun Y, Krag D
J Immunol Methods
. 2022 Sep;
510:113362.
PMID: 36174735
Background: Antibodies and other recognition molecules direct cancer cell death by multiple types of immune cells. Therapy directed at only one target typically results in tumor regrowth because of tumor...
3.
Pero S, Nagulapally A, Mei L, Zhang F, Sholler G, Krag D, et al.
Ann Clin Lab Sci
. 2022 Jul;
52(3):349-358.
PMID: 35777796
Objective: Tumor heterogeneity is a fundamental problem in treating cancer with monotargeting therapy, including chemical, antibody, and T cell therapies. Our goal is to target multiple mutated peptides found in...
4.
Shukla G, Pero S, Mei L, Hitchcox S, Fung M, Sprague J, et al.
J Immunol Methods
. 2021 Oct;
499:113157.
PMID: 34597620
Objective: Our goal was to develop a simpler and less expensive method of obtaining human clinical-grade WBCs using an alternative method to continuous leukapheresis. Our purpose for the WBCs is...
5.
Shukla G, Sun Y, Pero S, Krag D
J Immunol Methods
. 2019 Dec;
478:112720.
PMID: 31812660
Background: Antibodies that target a single tumor antigen fail to cure stage IV cancer patients due to tumor heterogeneity and variable expression of antigen. Tumor cells with insufficient binding of...
6.
Blenman K, He T, Frankel P, Ruel N, Schwartz E, Krag D, et al.
NPJ Breast Cancer
. 2018 Aug;
4:28.
PMID: 30155518
Tumor invasion into draining lymph nodes, especially sentinel lymph nodes (SLNs), is a key determinant of prognosis and treatment in breast cancer as part of the TNM staging system. Using...
7.
Shukla G, Sun Y, Pero S, Sholler G, Krag D
J Immunol Methods
. 2018 Jun;
460:51-62.
PMID: 29906453
The aim of this preclinical study was to evaluate T7 bacteriophage as a nanoparticle platform for expression of neoantigens that could allow rapid generation of vaccines for potential studies in...
8.
McDaniel J, Pero S, Voss W, Shukla G, Sun Y, Schaetzle S, et al.
Cancer Immunol Immunother
. 2018 Feb;
67(5):729-738.
PMID: 29427082
A better understanding of antitumor immune responses is the key to advancing the field of cancer immunotherapy. Endogenous immunity in cancer patients, such as circulating anticancer antibodies or tumor-reactive B...
9.
Shukla G, Pero S, Sun Y, Carman C, Harlow S, Krag D
J Immunol Methods
. 2018 Feb;
455:14-23.
PMID: 29382466
Autoantibodies to breast and other cancers are commonly present in cancer patients. A method to rapidly produce these anti-cancer autoantibodies in the lab would be valuable for understanding immune events...
10.
Shukla G, Olson W, Pero S, Sun Y, Carman C, Slingluff Jr C, et al.
J Transl Med
. 2017 Aug;
15(1):180.
PMID: 28851380
Background: Our research is focused on using the vaccine draining lymph node to better understand the immune response to cancer vaccines and as a possible source of anti-cancer reagents. We...